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Anaesthesia, surgery and life threatening allergic reactions. Epidemiology 
and clinical features of perioperative anaphylaxis: The 6
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 National Audit 
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Abstract (250 words) 
The 6th National Audit Project on perioperative anaphylaxis collected and reviewed 266 reports of 
grade 3-5 anaphylaxis over one year from all National Health Service hospitals. Estimated incidence 
is ≈1:10,000 anaesthetics. Case exclusion due to reporting delays or incomplete data means true 
incidence may be 70% higher. The distribution of 199 identified culprit agents was antibiotics 47%, 
neuromuscular blocking agents (NMBA) 33%, chlorhexidine 9% and Patent Blue dye (PBD) 4.5%. 
Teicoplanin comprised 12% of antibiotic exposures but caused 38% of antibiotic-induced 
anaphylaxis. Suxamethonium-induced anaphylaxis, mainly presenting with bronchospasm, was two-
fold more likely than other NMBAs. Atracurium-anaphylaxis mainly presented with hypotension. 
Non-depolarizing NMBAs had similar incidences to eachother.  There were no reports of latex-
induced anaphylaxis.  
Commonest presenting features were hypotension, (46%), bronchospasm (particularly in patients 
with morbidly obesity and asthma) (18%), tachycardia (9.8%), oxygen desaturation (4.7%), 
bradycardia (3%) and reduced/absent capnography trace (2.3%). All patients were hypotensive 
during the episode. Onset was rapid for NMBAs and antibiotics but delayed with chlorhexidine and 
PBD. There were ten deaths and 40 cardiac arrests. The review panel judged that cardiac 
compressions should be started in adults with systolic blood pressure <50mmHg. Pulseless electrical 
activity was the usual type of cardiac arrest, often with bradycardia. Poor outcomes were associated 
with increased ASA, obesity, beta blocker and or ACE-inhibitor medication. 
Seventy percent of cases were reported to the hospital incident reporting system and only 24% to 
Medicines and Healthcare Regulatory Authority via the Yellow Card Scheme.  
This paper describes summary findings from NAP6: the full report is at 
http://www.nationalauditprojects.org.uk/NAP6Report#pt  .    
 
Keywords: anaphylaxis; anaesthesia; allergy; National Audit Project 
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Anaphylaxis is defined as a severe, life-threatening generalized or systemic hypersensitivity 
reaction.1 Most anaphylactic reactions are allergic. Severity is commonly graded 1-5, though multiple 
grading systems exist. Mild reactions, grades 1 and 2, do not constitute anaphylaxis. NAP6 
investigated grades 3, 4 and 5 (fatal) reactions occurring in the perioperative period. 
 
Estimates of the incidence of perioperative anaphylaxis vary between 1:6,000 to 1:20,000 
anaesthetics.2 In a large French study, the estimated incidence of IgE-mediated perioperative 
hypersensitivity (grades 1-4) was 1:10,000 anaesthetics.3  
 
Perioperative anaphylaxis may vary over time and between different patient populations. Most 
studies have identified neuromuscular blocking agents (NMBAs) as the commonest cause. In a 
French study, latex was the second-commonest cause of anaphylaxis: unlike in a more recent UK 
study.4 
 
The majority of previous reports have included all grades of perioperative hypersensitivity and all 
report similar patterns of clinical features (Table 1). In a small number of cases, there may be single 
organ-system involvement 3 4  and cutaneous features predominate in mild, non-IgE mediated 
perioperative hypersensitivity 3 4. Most studies agree that the clinical features of severe anaphylaxis 
are very similar regardless of whether allergic or non-allergic,  
 
It is important to understand how severe anaphylaxis presents as there is a wide differential 
diagnosis, no bedside tests, and prompt, specific treatment is essential.5 6 7  
 
There are few large prospective studies of perioperative anaphylaxis with most looking 
retrospectively at cases that have been referred to allergy clinics for investigation. In addition, few 
studies have focused solely on severe (Grade 3-5) perioperative anaphylaxis or investigated 
relationships between presenting features and co-morbidities/concomitant medication. Individual 
trigger agents may elicit disparate patterns of presentation, including onset time, cardiovascular or 
respiratory system preponderance and outcomes may also differ.  
 
It is known that onset of anaphylaxis to chlorhexidine, latex and Patent Blue dye can be delayed 6 8–10 
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Methods 
Methods are discussed in detail in an accompanying paper.11 Denominator data were derived from 
the NAP6 Activity12 and Allergen Exposure 13 studies. 
 
Results 
We identified 266 cases of Grade 3-5 anaphylaxis meeting our inclusion criteria. A further 261 cases 
were excluded due to failure to provide information on allergy clinic investigation, lack of detail or 
being uninterpretable, as described in the Methods paper.11  
 
The Activity survey12 estimated that 3 126 067 anaesthetics are delivered in the UK each year, giving 
a calculated incidence of perioperative anaphylaxis of 1:11 752.  
 
In 148 cases the culprit was identified as ‘definite’ and in 51 cases as ‘probable’ (including seven 
cases where two probable culprits were identified), giving a total of 199 identified culprit agents. In 
15 cases the culprit was designated ‘possible’ and in 57 cases the culprit could not be identified. The 
most common cause of perioperative anaphylaxis was antibiotics, followed by NMBAs, chlorhexidine 
and Patent Blue dye (Table 1). 
 
(Table 1 near here) 
 
Fifty-eight percent of the anaphylactic events occurred in the operating theatre, of which 3% were 
before induction of anaesthesia, 81% after induction and before surgery, 13% during surgery and 3% 
after surgery.  
 
Clinical features 
The first clinical feature was hypotension (46%), bronchospasm/high airway pressure (18%), 
tachycardia (9.8%), cyanosis/oxygen desaturation (4.7%), bradycardia (3%) and reduced or absent 
capnography trace (2.3%). Three patients presented with cardiac arrest (1.2%). Bronchospasm was 
the presenting feature more frequently in morbidly obese compared with other patients and in 
(mainly well-controlled) asthmatic patients: (34%) compared with non-asthmatic patients (15%).   
 
(Figure 1 near here) 
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Presentation was similar regardless of whether the mechanism was allergic or non-allergic. In 
approximately 1 in 20 cases an awake patient reporting feeling unwell was the harbinger of 
anaphylaxis (Fig, 1). Fifteen (5.6%) patients presented with isolated cardiovascular features and four 
(1.5%) with isolated respiratory features. 
 
(Figure 2 near here) 
 
Hypotension as the presenting feature was proportionately more common in men than women, 
perhaps related to coronary artery disease (23.7% vs 8.4%), beta blockers (26.7% vs 11.2% and ACE-I 
medication (21.2% vs 15.2%). Bronchospasm was more common in women: more women had 
asthma (25% vs 15.5%) (Supplementary figure 1). 
 
There was a marked difference between NMBAs: bronchospasm was the most common 
presentation when suxamethonium was the trigger and hypotension with atracurium (Figure 3). 
 
(Figure 3 near here) 
 
Considering clinical features present at any time during the anaphylactic episode, hypotension was 
universal. Rash, seldom a presenting feature, developed in 56.4% of cases, bronchospasm/high 
airway pressure in 48.5%, tachycardia in 46.2%, cyanosis/oxygen desaturation in 41.4% and a 
reduced/absent capnograph trace in 32.7%. Bronchospasm at any time was also seen in a higher 
proportion of patients with asthma (59%) than others (46%). Again, this clinical pattern was very 
similar in the subgroup of allergic anaphylaxis patients (Figure 4). 
 
Two notable features were almost absent. Rash was an uncommon presenting feature and was 
notably rare at any time in the most serious of cases. Airway problems were also rarely seen. A 
single patient required a front of neck airway to manage laryngeal oedema but there were no other 
presentations or significant clinical features of airway difficulty. 
 
(Figure 4 near here)  
 
Considering all cases, onset time was < 5 min in 66.2%; < 10 min in 82.7%; < 15 min in 87.6% and < 
30 min in 94.7%. Onset times for individual agents are discussed below. 
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Fatalities, cardiac arrests and profound hypotension 
Ten patients died directly (eight) or indirectly (two) due to anaphylaxis, equating to an incidence of 
perioperative death from anaphylaxis of 1 in 313 000 and a per case mortality rate of 1 in 26.6 cases. 
All fatalities were aged >46 yrs and half aged >66. Two were ASA 2, six ASA 3 and two ASA 4. In the 
Activity  survey12 25% of patients were aged >66 yrs, 77% were ASA 1-2 and <2% ASA 4-5. 
 
Only one patent was of normal weight; four were overweight, one obese and four morbidly obese. 
In the Activity Survey 12  21% of all patients were obese or morbidly obese. None of the patients who 
died had a history of atopy or asthma. Five had coronary artery disease, most of whom were 
undergoing non-cardiac surgery; six were taking beta blockers and six ACE inhibitors. Three were 
taking both and one patient neither drug. Amongst the 266 reports of life-threatening anaphylaxis 
14.7% had evidence of coronary artery disease, 17.4% were taking beta-blockers and 17.1% were 
taking ACE inhibitors.  
 
Three patients were undergoing cardiac surgery. The surgical procedure was abandoned in nine 
cases and proceeded in one. Cardiac arrest was PEA in all fatal cases, none preceded by significant 
arrhythmias, though there was bradycardia in two. The clinical features (presenting, and at any time 
during the episode) of the ten fatal cases are shown in Figure 5. Management of these cases is 
described in the accompanying paper 14  
 
(Figure 5 near here) 
 
Forty (15%) patients, all of whom were adults, experienced cardiac arrest, including nine of the 
patients who died. Thirty-one (77.5%) survived. Most (81%) events occurred after induction of 
anaesthesia and before surgery. A consultant was involved in all resuscitations. No particular trigger-
agents were associated with a higher risk of cardiac arrest. However, survivors of cardiac arrest were 
younger, fitter and less comorbid than patients who died (Table 3).  
 
(Table 3 near here) 
 
The presenting features are shown in Figure 6. Hypotension and bronchospasm/raised airway 
pressure were prominent, and rash notably uncommon. Reduced or absent capnogram trace was 
not recorded as a presenting feature in any cases. Bradycardia was more common than tachycardia. 
Cardiovascular presenting features occurred in 25, respiratory in 11 and others in four. Of all cardiac 
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arrests 34 were pulseless electrical activity (PEA), 4 VF/VT and 2 asystole. Only six patients 
developed an arrhythmia prior to cardiac arrest: four bradycardia and two ventricular tachycardia. 
There were no reports of atrial fibrillation or supraventricular tachycardia.  
 
(Figure 6 near here) 
 
Harm, as a result of anaphylaxis was judged to occur in 10 (32%) of 31 survivors. Sequelae included 
new anxiety, a change in mood, impaired memory, impaired coordination, impaired mobility, 
symptoms of PTSD, myocardial damage, heart failure and new renal impairment were reported. 
 
In adult patients the lowest BP recorded in the first hour after the event was ‘unrecordable’ in 56 
(21%) cases, <50 mmHg in 58 (22%) cases and 51-59mmHg in 53 (20%) cases. 
 
Antibiotics 
Ninety-two cases of antibiotic-induced anaphylaxis were identified (including 94 definite of probably 
antibiotic culprits): 48% of all cases with identified culprits. The majority were caused by co-
amoxiclav or teicoplanin, between them accounting for 89% of identified antibiotic culprits. The 
overall incidence of reported antibiotic-induced anaphylaxis was 4.0 per 100,000 exposures. The 
highest incidence was seen with teicoplanin (16.4 per 100 000 exposures) then co-amoxiclav (8.7 per 
100 000 exposures). The relative anaphylaxis rate using cefuroxime as an index was 17.4 for 
teicoplanin and 9.2 for co-amoxiclav (Table 4) 
 
The onset of anaphylaxis was within 5 minutes in 74% of cases; 18% between 6-10 minutes; 5% 
between 11-15 minutes, 2% between 16-30 minutes. None were delayed >30 minutes. 
 
Of the 36 patients who reacted to teicoplanin, 20 (56%) stated preoperatively they were allergic to 
penicillin. Of the 36 reactions 16 were grade 3, 18 grade 4 and two grade 5. Ten developed 
moderate and two severe harm (death). Amongst the 20 who likely received teicoplanin because of 
a history of allergy, two reactions were grade 4 and one grade 5, six developed moderate harm and 
one died. The NAP6 Allergen survey13 demonstrated the choice of antibiotic was influenced by 
preoperative allergy history in a quarter of patients who received teicoplanin or vancomycin. 
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In less than 1% of cases, communication failure led to an antibiotic being administered despite a 
relevant positive allergy history. Two cases were judged preventable by better allergy history 
communication.  
 
Eighteen antibiotic related reactions related to test doses: in ten cases the patient reacted to the 
test dose itself (52.6%), which ranged from 5 – 30% of the therapeutic dose, and the other eight 
patients reacted to the full dose, which was given within 1 minute of the test dose in all but one case 
(given within 10 minutes). There was no evidence that administration of a ‘test dose’ of antibiotic 
reduced the severity of an ensuing reaction. On the contrary, in cases of anaphylaxis caused by an 
antibiotic where a test dose had been given, a greater proportion of severe reactions (Grade 4 and 
5) was seen than if no test dose had been given (58% vs 51%). Of the ten deaths, four were judged 
to be due to an antibiotic. 
 
Neuromuscular blocking agents and reversal agents 
Sixty-five cases of anaphylaxis were triggered by NMBAs, 25% of all cases and 32% of cases leading 
to death or cardiac arrest. Ninety-five percent of NMBA-induced reactions presented within 5 
minutes. 
 
The culprit NMBAs were rocuronium (42% of cases), atracurium (35%), suxamethonium (22%) and 
mivacurium (1.5%). There were no cases of anaphylaxis due to vecuronium, pancuronium or 
cisatracurium, though these only account for 4.4% of all NMBA use.13 The review panel identified 
non-allergic anaphylaxis to atracurium in three cases, and to mivacurium in a single case. Incidence 
per 100 000 exposures is a more meaningful metric than occurrence rate. The overall incidence of 
reported NMBA-induced anaphylaxis was 5.3 per 100 000 exposures. The highest incidence was seen 
with suxamethonium (11.1 per 100 000 exposures) while all others were similar to each other. 
Suxamethonium was twice as likely to cause anaphylaxis than any other NMBA (Table 5) 
 
In 71% of cases where the anaesthetist suspected an NMBA, the culprit was confirmed by the panel 
and in 14.3% an alternative culprit was identified. The ratio of suspected/confirmed cases was 1.4 
for atracurium, 1.3 for rocuronium and 1.1 for suxamethonium (Table 5). 
 
(Table 5 near here) 
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Previous exposure to pholcodine was recorded in only two patients, both of whom had NMBA-
induced anaphylaxis (rocuronium and suxamethonium) but no conclusions can be drawn due to very 
limited recording of pholcodine exposure. No episodes were due to neostigmine. The anaesthetist 
suspected that sugammadex was the suspected trigger agent in two cases, and one of these was 
confirmed by the review panel. 
 
Chlorhexidine 
There were 18 cases of chlorhexidine-induced anaphylaxis, representing 9% of culprits. The Allergen 
survey13 identified 2 298 567 exposures to chlorhexidine by at least one route annually (73.5% of all 
cases). Based on NAP6 data, the incidence of anaphylaxis to chlorhexidine is 0.78 per 100 000 
exposures, likely an over-estimate as almost all patients are exposed to chlorhexidine during 
anaesthesia and surgery. 
Despite reporting chlorhexidine allergy prior to the event, one patient was exposed resulting in 
anaphylaxis. One patient reported a prior reaction during anaesthesia that was not investigated and 
reacted to chlorhexidine when exposed. One patient experienced a subsequent reaction to 
chlorhexidine despite confirmation of allergy to chlorhexidine following investigation of the index 
NAP 6 event. There was one fatal reaction. Eight reactions were grade 4 and nine were grade 3. 
Consistent with published data, most cases were in males (16/18). Ten were ASA grade 2 and eight 
ASA grade 3. Urology (6), cardiac (3) and orthopaedic (3) surgery accounted for the majority of cases.  
The anaesthetist suspected chlorhexidine in only five (28%) cases. Reactions to cutaneous 
chlorhexidine was mostly slower than other agents and of lower grade. There was quicker onset and 
greater severity in patients with exposure via a coated central venous catheter (mostly onset <5 
minutes of exposure and grade 4 events) than those with only topical surgical site exposure (mostly 
onset at 1 hour and grade 3 events).  
Approximately two thirds of cases presented with hypotension and none presented with 
bronchospasm (Supplementary figure 2x) 
Patent Blue dye 
We identified nine (3.4%) cases of Patent Blue dye-induced anaphylaxis, five grade 3 and four grade 
4. Based on an estimated 61,768 annual exposures,13 the incidence of anaphylaxis to Patent Blue 
was 14.6/100,000 administrations (higher than suxamethonium). All patients were female: eight 
were scheduled for breast cancer surgery, which was abandoned in two cases.   
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Onset was slower than other trigger agents with only two cases <5 mins, four presented after >15 
mins including two after >60 mins. Hypotension was the commonest presentation: all patients 
became significantly hypotensive and in three cases systolic blood pressure fell below <50mmHg. 
Four patients desaturated to <90%. Cutaneous features were present in six patients.   
All cases were resuscitated successfully and no long-term physical sequelae were reported.   
Miscellaneous trigger agents 
We identified three cases of anaphylaxis to succinylated gelatin solutions and two to blood products. 
Ondansetron, propofol, aprotinin, protamine and ibuprofen were responsible for a very small 
number of cases. The Allergen survey estimated that 48 203 UK patients are exposed to gelatin-
based IV fluids during anaesthesia each year,13 giving an approximate incidence of 6.2 per 100 000 
administrations, a rate similar to rocuronium. 
 
Reporting 
As reporting is a positive action; it was inferred that this did not take place where the information 
was not provided. Nine percent of cases were reported to Medicines and Healthcare products 
Regulatory Authority (MHRA) by the anaesthetist, 8.3% by the local co-ordinator, 3% by the allergy 
clinic and 2.6% by others, including critical care. Only three deaths and nine of 31 who survived 
cardiac arrest (29% combined) were reported to the MHRA.  
 
Reporting to the Trust's critical reporting incident system was performed in 70.3% of cases (including 
eight of ten deaths and 24 (77%) of 31 cardiac arrest survivors). Of these 187 cases, 160 were 
reported by an anaesthetist, six by the nursing team and five by the surgical team. 
 
Discussion 
The overall incidence of perioperative anaphylaxis was estimated to be 1 in 10 000 anaesthetics. This 
is likely an under-estimate: we received 541 reports over a one-year period; 412 had Part A and Part 
B completed and only 266 NHS cases met inclusion criteria, were interpretable and were 
grade 3-5 anaphylaxis. Inability to interpret reports was predominantly due to lack of 
information, usually as a result of uncertainty about the comprehensiveness of allergy clinic 
testing. Of the reviewed cases only 17 were not anaphylaxis or were Grade 2, suggesting 
that the true incidence could be up to 70% higher than our estimate. Previous estimates are 
similar but the majority included perioperative hypersensitivity of all grades: despite 
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including only Grades 3 to 5, our estimated incidence is at least as high. It is possible that 
the incidence of perioperative anaphylaxis is rising, perhaps as a result of increasing 
antibiotic sensitization in the population, and it is notable that antibiotics have overtaken 
NMBAs as the most frequent trigger agent. Irrespective of absolute incidences, because of 
our methodology we believe our results accurately represent the relative incidence with 
different trigger agents. 
 
Presenting features 
Perioperative anaphylaxis has several unusual if not unique elements. First the vast majority of 
triggers are administered IV, therefore having the potential for the most rapid and severe reactions. 
Second multiple drugs are administered almost concurrently. These routinely alter normal 
physiology such that hypotension, arrhythmia, bronchospasm and even rash may be more 
commonly due to causes other than anaphylaxis. Lastly the events occur in the immediate presence 
of a trained ‘resuscitationist’ who may be able to identify and manage the event more promptly 
than in many other settings.  
 
Variation in presenting clinical features between different patient groups, with different drugs and 
with different severity of reactions are all notable and add to the available literature. It is worth 
noting that hypotension was universal. Bronchospasm was less common but was more often seen in 
the obese and those with pre-existing asthma. Rash was rarely present, sometimes missed (the 
patient hidden under drapes) and was particularly uncommon in the most severe cases, often only 
occurring when blood pressure and presumably perfusion had been restored. Bradycardia was 
relatively common, again in the more severe events and arrhythmias were rare. Airway 
complications were almost absent. 
 
Fatalities 
Our data suggest that perioperative anaphylaxis was more likely to be fatal in patients who were 
older, of a higher ASA class and significantly obese. Unlike anaphylaxis in the community.15 we found 
no evidence of asthma as a risk factor for fatal perioperative anaphylaxis, but coronary artery 
disease and administration of beta blockers and or ACE inhibitors were prominent. Patients died 
despite prolonged attempts at resuscitation, with most aspects of care being rated as good 
(described in detail in the accompanying paper14). 
 
Cardiac arrest and survivors. 
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Most patients who survived cardiac arrest were younger and fitter than those who died. Prescription 
of ACEI again was prominent in those who developed cardiac arrest. A considerable majority were 
PEA and the absence of tachyarrythmias either as a primary event or secondary to adrenaline 
administration is notable.  
 
Profound hypotension 
A group of patients who had profound hypotension, without being designated as ‘in cardiac arrest’, 
was identified during review as an apparently high risk cohort with some poor outcomes. There was 
discussion regarding the point at which cardiac compressions should be started and, after seeking 
wide expert advice, we decided this should be 50mmHg, so any patient with a lowest systolic blood 
pressure <50mmHg was designated as requiring CPR, and therefore grade 4, and where cardiac 
compressions were not started this was judged to have been an omission. This is a newly identified 
group and perhaps contentious. Their management and outcomes are discussed in the.14 
 
Antibiotics 
In contrast to many published series3 16 17 antibiotics, not NMBAs, were the most common cause of 
perioperative anaphylaxis. The high frequency of teicoplanin-induced anaphylaxis is noteworthy and 
likely presents an upward trend. Our findings demonstrate that administration of teicoplanin is 
closely related to patient-reported penicillin allergy, the most commonly reported drug allergy in the 
community with up to 10% of the population labelled as allergic. It is likely that the majority are 
mislabelled and that at least 90% could be de-labelled if an adequate description of the original 
reaction could be obtained or the patient investigated in an all rgy clinic.18 
 
Considerably more than half of all patients received an antibiotic and almost all were administered 
after induction of anaesthesia. In three quarters, signs of anaphylaxis were identified in <5 minutes, 
and almost all in <10 minutes. Anaphylaxis-induced hypotension is likely to be exacerbated by 
general or neuraxial anaesthesia. There is a strong argument for antibiotics to be administered 
several minutes before induction of anaesthesia. There are several potential benefits; first, lack of 
allergy can be confirmed with the patient immediately before administration, second, the severity of 
physiological derangement due to anaphylaxis may be lessened and third, investigation of 
anaphylaxis is considerably simplified if fewer drugs have been administered. 
 
It is likely that some of the anaphylactic reactions to antibiotics could have been avoided. Perversely, 
this is particularly likely to be the case in patents reported to be allergic to penicillin who were then 
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given teicoplanin, which we have shown has a 17-fold higher risk of anaphylaxis than flucloxacillin 
(or cefuroxime). If it were possible to identify the >90% of patients who report penicillin allergy, but 
who are not, then avoidance of second line antibiotics would likely lessen overall risk of 
perioperative anaphylaxis significantly. Of note, second line antibiotics are more expensive and are  
associated with increased duration of treatment, hospital stay and antibiotic resistance.19–21 It is 
currently impractical for all putative penicillin allergy to be investigated in allergy clinics 
preoperatively, and the process is significantly complex. However, with the ever increasing 
importance of antibiotic stewardship, avoidance of a spurious label of ‘penicillin- allergic’ is an area 
ripe for research.   
 
Thirteen patients with anaphylaxis due to co-amoxiclav and four of those with anaphylaxis to 
teicoplanin had received an IV ‘test dose’ of between 5%-30% of the therapeutic dose. It cannot 
reasonably be expected that a single test dose will eliminate the risk of anaphylaxis.  In the allergy 
clinic the starting dose for drug challenge (which starts only after negative skin testing) will vary 
depending on: the severity of the index reaction, the dose that is believed to have caused it, the 
patient's concurrent comorbidities, whether the challenge is oral or intravenous and the drug itself. 
With some high-risk drug challenges this can be as low as 10-9 of the therapeutic dose increasing in 
2-10 fold increments. Indeed, NAP6 provides evidence that anaphylaxis occurring after a test dose is 
at least as severe as after a full dose. A third of UK anaesthetists routinely administer a test dose 
when administering an IV antibiotic,22 despite  guidelines from the Association of Anaesthetists of 
Great Britain and Ireland (AAGBI) advising against their use6 and we find no evidence to support the 
practice. 
 
NMBA and reversal agents 
In previous studies NMBAs were responsible for 40-66% of all cases of perioperative anaphylaxis17 23.  
 
Sensitization to NMBAs may occur during anaesthesia but the majority of patients do not give a 
history of previous exposure,24 and environmental exposure to the quaternary ammonium (QA) 
epitope has been implicated in generating NMBA allergy.25 In addition, pholcodine-containing cough 
medicines may cause sensitization to NMBAs26 and NMBA-sensitization has declined in Norway since 
withdrawal of pholcodine cough medicine.27  
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Non-allergic anaphylaxis may occur with atracurium and mivacurium. Recent evidence implicates 
specific receptors on the surface of mast cells.28 Variation in receptor expression may explain why 
these drugs cause dramatic non-IgE mediated mediator release in some individuals. 
 
No previous study has undertaken parallel investigation of incidence and NMBA exposure. Studies 
relying on sales of drug ampoules to estimate the number of patient-exposures may not estimate 
the denominator accurately. Ampoule sales of suxamethonium likely overestimate usage as a result 
of waste. To avoid these pitfalls, NAP6 surveyed the number of patients receiving NMBAs during the 
same year as the case-reporting phase. 
 
NMBAs accounted for approximately one third fewer cases of anaphylaxis than antibiotics, but carry 
at least as high a risk as antibiotics per administration, with the exception of teicoplanin. The lower 
occurrence rate of NMBA-induced anaphylaxis observed is due to ≈2.5 million administrations of 
antibiotics to surgical patients per year compared to ≈1.2 million administrations of NMBAs. 
Suxamethonium is well known to carry a greater risk of anaphylaxis than other NMBAs. Our data 
confirm this. The risk of suxamethonium-induced anaphylaxis was approximately twice that of all 
other NMBAs. 
 
Sadleir and colleagues have suggested that rocuronium is associated with a relatively higher risk of 
anaphylaxis than vecuronium (Sadleir et al., 2013). In that study the incidence of suxamethonium-
anaphylaxis could not be accurately estimated, through lack of denominator data. Vecuronium is 
used only rarely in the UK.13 Although our data cannot be definitive regarding the relative incidence 
of atracurium and rocuronium-induced anaphylaxis: we identified no major difference in their 
observed incidences. The difficulties inherent in interpreting the reported incidences of uncommon 
anaphylactic events are described by Laake and colleagues30. In particular, marginal under-reporting 
has a disproportionately-large effect on calculated incidence. Anaesthetists tended to overestimate 
the number of cases caused by NMBAs, perhaps as a result of their well-known allergenic potential. 
 
We are unable to comment on the possible influence of pholcodine consumption on the incidence of 
NMBA-anaphylaxis. This information was not recorded in two thirds of reports: only 18% of allergy 
clinics routinely seek this information.31 
  
A single case of sugammadex-induced anaphylaxis was reported. Onset was delayed, and 
anaphylaxis should be considered among other differential diagnoses if a patient deteriorates in the 
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recovery room. Sugammadex was used as treatment for anaphylaxis and this is discussed in the 
accompanying paper.14 
 
Chlorhexidine 
Perioperative chlorhexidine exposure may occur via topical skin disinfection, chlorhexidine-coated 
central venous catheters (CVC) and the use of chlorhexidine containing lubricating gels.8 It may not 
be immediately obvious that these products contain chlorhexidine, which has been called "the 
hidden allergen."32 
There are geographical differences in the incidence of chlorhexidine-induced perioperative 
anaphylaxis. 7.7% in the United Kingdom33 and 9.3% in Denmark;34 but it is a rare allergen in 
France.35 The cause for the variation is not clear but may be related to under-recognition and 
differences in practice (e.g. more use of povidone-iodine and lower use of chlorhexidine coated 
catheters). As exposure to chlorhexidine is highly likely in any surgical setting several centres 
routinely test all patients referred with perioperative anaphylaxis for chlorhexidine allergy. In 
countries adopting this practice chlorhexidine allergy is commonly identified.33 34 
Sensitisation to chlorhexidine can occur in health care or the community as chlorhexidine-containing 
products are found in both environments. 36 37 The true prevalence of chlorhexidine allergy remains 
unknown. During a ten year period up to 2004 only 50 cases of IgE-mediated reactions were 
reported in the medical literature. More recently, 104 cases were reported, from four UK specialist 
centres covering only 2009-2013.9  
Chlorhexidine is not yet considered among the ‘mainstream’ causes of perioperative anaphylaxis, 
despite evidence to the contrary. This is reflected by lost opportunities during perioperative history 
taking, and the low suspicion rate we observed. In previous studies up to 80% of patients diagnosed 
with chlorhexidine allergy reported possible chlorhexidine allergy that could have been identified 
prior to their adverse reaction.38 39 
Despite an alert relating to chlorhexidine-containing medical products and devices being issued 
nationally by MHRA in 2012,40 it appears that many clinical staff are unaware of which products 
contain this antiseptic and the risks of anaphylaxis. 
 
It is unsurprising that reactions are more rapid and severe when a CVC is the source of the 
chlorhexidine and the allergen is delivered directly to the circulation. Removing the CVC is central to 
treating the reaction under these circumstances. 
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Patent blue 
Patent Blue dye is found as a food dye (E131), approved for use in the UK but not in the USA, 
Australasia, Japan, and several other countries. It structurally resembles other triarylmethane dyes 
widely-used in manufacturing. During surgery it may be injected into the tissues and taken up by the 
lymphatic system enabling sentinel lymph nodes to be seen directly. Sensitization is likely due to 
environmental exposure to the dye or a cross-reacting epitope.  
 
The reported estimated incidence of allergic reactions, which are commonly mild, varies between 
150 to 1000 per 100 0000 administrations.10 41–43 Reactions are frequently delayed, at 30-60 mins, 
possibly due to slow absorption from subcutaneous tissues and lymphatics.42  
 
As Patent Blue dye interferes with pulse oximetry (causing spuriously-low readings) this has the 
potential to delay recognition of the onset of anaphylaxis. While two studies examining this effect 
reported mean reductions in digital oxygen saturation (SpO2) of <2%,10 44 in some individuals 
considerably greater falls in oximetry values may be observed.45 46 . 
 
In NAP6 reactions to Patent Blue dye were relatively common, were severe and required significant 
resuscitation. Cutaneous signs were absent in a third of patients and absence of rash should not 
dominate the differential diagnosis. As hypoxaemia is common after perioperative anaphylaxis, any 
fall in oxygen saturation should be assumed to be real until blood gas analysis has ruled this out.  
 
Miscellaneous agents 
The very small number of cases of reactions to blood products (and none to red blood cells) is 
notable. The activity survey estimated approximately 84 000 perioperative administrations of blood 
products. The relative infrequency of these is perhaps attributable to the success of the serious 
hazards of transfusion (SHOT) haemovigillance scheme https://www.shotuk.org/.  
 
Ondansetron is administered during an estimated 77% of general anaesthetics and 66% of all cases 
involving anaesthetist delivered care.13 A single report of ondansetron-induced anaphylaxis indicates 
its  extreme rarity. However, these reactions may be severe: two cases of fatal anaphylaxis 
attributed to ondansetron have been reported 47.  
 
We observed a single case of propofol allergy. Propofol is an extremely-uncommon cause of 
anaphylaxis. Our survey data indicate that well over two-million patients in the UK are exposed to 
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this induction agent perioperatively each year.13 Twenty-four IgE-mediated cases were reported in a 
French eight-year study48 and two cases were recorded in a UK seven-year single-clinic study. 4 
Asserhøj and colleagues suggested that propofol-induced anaphylaxis may occur in some patients 
via a non-IgE-mediated mechanism.49 Skin testing is negative in this situation, and controlled 
provocation testing with IV propofol would be necessary to confirm the diagnosis: a procedure that 
is not generally available. The same publication dispelled the notion that propofol is contra-indicated 
in adults who are allergic to egg, soya or peanut, but some uncertainty still exists in egg-allergic 
children.50 A diagnosis of hypersensitivity to propofol has serious implications for the patient, given 
the ubiquity of this induction agent and therefore merits full investigation.  
 
We recorded one case of anaphylaxis to protamine in a patient with diabetes. It has been suggested 
that patients who have been exposed to Neutral Protamine Hagedorn insulin, which contains 
protamine, are more likely to experience protamine-induced anaphylaxis.51 Fish allergy has been 
implicated as a risk factor for protamine-anaphylaxis as protamine is traditionally extracted from the 
sperm of fish. It is possible that the drug will be increasingly synthesised by recombinant 
biotechnology.  Sensitization to the fish-derived product may be unlikely to result in anaphylaxis 
when a patient is exposed to the recombinant formulation. 
 
Anaphylaxis due to non-steroidal anti-inflammatory drugs (NSAIDs) has been comprehensively 
reviewed by Kowalski and colleagues.52 There is a wide spectrum of severity and pathogenesis. 
Reactions are commonly non-immunologically mediated and there may be cross-reactivity to drugs 
sharing COX-1 enzyme inhibition. An eight-year national study in France identified only three 
immunologically-mediated perioperative hypersensitivity reactions to NSAIDs.48 
 
Reporting 
Reporting rates are disappointingly-low. All NAP6 cases were at least Grade 3, representing a life-
threatening incident, yet almost a third were not reported to the hospital's critical incident reporting 
system, reducing the likelihood of lessons being learned where applicable. Only a quarter of cases 
were reported to the MHRA, despite AAGBI guidance, irrespective of severity of the outcome. Local 
Co-ordinators were responsible for many of the reports to MHRA, and it is unlikely that these would 
have been reported either by the index anaesthetist or the allergy clinic. Our data imply that 
pharmacovigilance is not being supported adequately and further mean that data reported back to 
anaesthetists and allergy clinics by the MHRA is likely to be unreliable. Factors contributing to poor 
reporting-rates have been discussed by Mahajan.53  
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Conclusions 
We believe this is the largest study of life-threatening perioperative anaphylaxis incorporating 
contemporaneous real-life data on exposure to potential allergens, permitting calculation of 
accurate relative-incidence rates. We highlight antibiotic allergy as an increasing problem, 
particularly teicoplanin and suggest that optimizing pre-operative allergy history could reduce the 
number of perioperative anaphylactic reactions. We hope our data have finally dispelled any notion 
that test doses might prevent or ameliorate anaphylaxis. An awake patient is able to report early 
symptoms of evolving anaphylaxis and our data support administering antibiotics before induction 
of anaesthesia if practicable. Early recognition is key to successful treatment and our results show 
that initial presentation can be varied, likely to be bronchospasm if suxamethonium is the trigger 
agent, and may be delayed, particularly with Patent Blue dye and some exposures to chlorhexidine, 
the 'hidden allergen'. We point to the ways in which patient factors e.g. ASA grade, obesity, beta 
blockers and ACEI influence clinical features of perioperative anaphylaxis, a dimension previously 
under-reported. We do not believe that the risk of anaphylaxis should be a determining factor in the 
choice of non-depolarizing NMBAs. We urge anaesthetists to report cases through the MHRA Yellow 
Card Scheme so that pharmacovigilance can be better supported in the future. This is the first of two 
companion papers describing the main findings of NAP6; in the second14 we describe clinical 
management and outcomes and make recommendations for organizational and individual practice. 
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Table 1. Cases attributable to the four most common trigger-agents 
 
 Total 
number 
of cases 
Antibiotic NMBA Chlorhexidine Patent 
Blue Dye 
Definite 148 67 49 14 8 
Probable 51 27 16 4 1 
Total identified 199 94 (47.2%) 65 (32.7%) 18 (9.1%) 9 (4.5%) 
 
Table 2. Comparison of patients who survived or died after perioperative anaphylaxis. 
 Died after anaphylaxis 
n=10 
Survived anaphylaxis 
N = 256 
Aged >66 yrs 40% 31% 
Obese or morbidly obese 50% 36% 
Coronary artery disease 50% 13% 
Taking beta blocker 60% 15% 
Taking antiotensin converting 
enzyme inhibitor  
60% 21% 
Asthma 0% 21% 
 
Table 3. Characteristics of patients who died, compared to those who survived cardiac arrest, or 
experienced profound hypotension or did not experience profound hypotension.  
 
 Deaths 
 (n=10) 
Non-fatal 
cardiac arrest 
(n=31) 
BP <50mmHG 
without cardiac 
arrest or death 
(n=79) 
All others 
(n=135) 
 
Patient characteristics 
 
Age >66 
 
50% 35% 33% 34% 
 
ASA≥3 
 
80% 13% 33% 27% 
 
Obesity 50% 
 
31% 34% 43% 
CAD 
 
55% 8% 15% 14% 
Beta blocker 
 
60% 7% 14% 
 
19% 
ACEI 
 
60% 32% 9% 17% 
Asthma 
 
0% 14%   
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Table 4. Estimated incidences for antibiotic-induced anaphylaxis with definite or probable 
attribution in NAP6. *annual usage identified from Allergen survey 
13
 
 
 
 
Table 5. NMBAs confirmed as causative agents by the panel, absolute and relative risk.  *Data 
from the NAP6 Allergen survey 
13
  
  Culprits 
identified by 
the review 
panel 
Proportion 
of 
antibiotic 
usage* 
Patients 
receiving 
the drug per 
annum* 
Anaphylaxis 
rate 
/100,000 
administrations 
Relative rates 
(cefuroxime = 1) 
Co-amoxiclav 46 29.8% 532,580 8.7 9.2 
Teicoplanin 36 12.3% 219,621 16.4 17.4 
Cefuroxime 4 23.7% 424,143 0.94 1.0 
Gentamicin 3 34.5% 616,899 0.49 0.5 
Flucloxacillin 2 11.9% 211,973 0.94 1.0 
Piperacillin-
tazobactam 
1 1.6% 28,237 3.5 3.7 
Vancomycin 1 1.0% 17,648 5.7 6.1 
Metronidazole 1 15.2% 272,173 0.37 0.4 
Total (all 
antibiotic 
administrations) 
94 culprits 
(92 cases) 
100% 2,323,274 
 
4.0 
 
4.2 
 Cases 
suspected by 
anaesthetist 
Cases 
confirmed 
by review 
panel  
Proportio
n of UK 
NMBA 
usage* 
Patients 
receiving 
the drug 
per 
annum*  
Anaphylaxis 
rate/100,000 
administrations  
Relative risk of 
anaphylaxis 
(atracurium = 1) 
Atracurium 32 23 49.1% 554,543 4.15 1 
Rocuronium 34 27 40.6% 459,047 5.88 1.42 
Suxamethonium 16 14 11.2% 126,086 11.1 2.67 
Mivacurium 0 1 2.7% 30,786 3.25 0.78 
Vecuronium 0 0 2.2% 24,315 -  
Cisatracurium 0 0 1.6% 18,629 -  
Pancuronium 0 0 0.6% 7,059 -  
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Figure 1. First clinical feature (%) in allergic anaphylaxis and all patients with grade 3-5 
perioperative anaphylaxis. 
 
 
 
 
 
 
Figure 2. Presenting feature and body habitus in grade 3-5 perioperative anaphylaxis. 
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Figure 3. Initial features of Grade 3-5 Neuromuscular blocking agent-induced anaphylaxis 
 
 
Figure 4. Clinical feature (%) present at any time during grade 3-5 perioperative anaphylaxis: 
allergic anaphylaxis and all patients  
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Figure 5. Clinical features of ten fatal cases of perioperative anaphylaxis (presenting, and at any 
time during the episode). Orange, presenting feature, blue, during event. 
 
 
 
Figure 6. Clinical features of 37 non-fatal cardiac arrests from perioperative anaphylaxis 
(presenting, and at any time). Orange, presenting feature, blue, during event. 
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